Class information for:
Level 1: VINORELBINE//GEMCITABINE//ADVANCED NON SMALL CELL LUNG CANCER

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
1328 2615 31.4 69%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
823 11253 NON SMALL CELL LUNG CANCER//XRCC1//GEFITINIB

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 VINORELBINE Author keyword 59 24% 8% 220
2 GEMCITABINE Author keyword 43 11% 15% 389
3 ADVANCED NON SMALL CELL LUNG CANCER Author keyword 23 36% 2% 50
4 PERFORMANCE STATUS 2 Author keyword 18 89% 0% 8
5 NON PLATINUM REGIMEN Author keyword 9 83% 0% 5
6 ADVANCED NONSMALL CELL LUNG CANCER Author keyword 8 75% 0% 6
7 VINDESINE Author keyword 8 25% 1% 28
8 PULM DIS 1 Address 8 62% 0% 8
9 NONSMALL CELL LUNG CANCER Author keyword 7 11% 2% 60
10 NONSMALL CELL LUNG CARCINOMA Author keyword 7 20% 1% 30

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 VINORELBINE 59 24% 8% 220 Search VINORELBINE Search VINORELBINE
2 GEMCITABINE 43 11% 15% 389 Search GEMCITABINE Search GEMCITABINE
3 ADVANCED NON SMALL CELL LUNG CANCER 23 36% 2% 50 Search ADVANCED+NON+SMALL+CELL+LUNG+CANCER Search ADVANCED+NON+SMALL+CELL+LUNG+CANCER
4 PERFORMANCE STATUS 2 18 89% 0% 8 Search PERFORMANCE+STATUS+2 Search PERFORMANCE+STATUS+2
5 NON PLATINUM REGIMEN 9 83% 0% 5 Search NON+PLATINUM+REGIMEN Search NON+PLATINUM+REGIMEN
6 ADVANCED NONSMALL CELL LUNG CANCER 8 75% 0% 6 Search ADVANCED+NONSMALL+CELL+LUNG+CANCER Search ADVANCED+NONSMALL+CELL+LUNG+CANCER
7 VINDESINE 8 25% 1% 28 Search VINDESINE Search VINDESINE
8 NONSMALL CELL LUNG CANCER 7 11% 2% 60 Search NONSMALL+CELL+LUNG+CANCER Search NONSMALL+CELL+LUNG+CANCER
9 NONSMALL CELL LUNG CARCINOMA 7 20% 1% 30 Search NONSMALL+CELL+LUNG+CARCINOMA Search NONSMALL+CELL+LUNG+CARCINOMA
10 PHASE II STUDY 5 11% 2% 48 Search PHASE+II+STUDY Search PHASE+II+STUDY

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 VINORELBINE 153 35% 13% 350
2 GEMCITABINE PLUS VINORELBINE 98 84% 2% 53
3 VINDESINE 81 45% 5% 135
4 SUPPORTIVE CARE 66 20% 11% 289
5 GEMCITABINE PLUS 42 74% 1% 31
6 STAGE IIIB 37 42% 3% 68
7 DOCETAXEL PLUS 35 86% 1% 18
8 ACTIVE REGIMENS 34 93% 0% 13
9 COMPARING CISPLATIN 31 39% 2% 64
10 PACLITAXEL PLUS CARBOPLATIN 28 42% 2% 52

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of randomized controlled trials 2008 74 30 77%
First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer A Systematic Review 2010 63 63 73%
Treatment of non-small cell lung cancer (NSCLC) 2013 23 46 65%
Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer - A meta-analysis 2004 161 63 87%
A systematic review of the clinical effectiveness of first-line chemotherapy for adult patients with locally advanced or metastatic non-small cell lung cancer 2015 2 35 54%
American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003 2004 705 257 20%
New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions 1998 233 82 68%
First- and second-line therapy for advanced nonsmall cell lung cancer 2009 27 141 78%
Treatment of advanced non-small-cell lung cancer in the elderly: Results of an international expert panel 2005 115 79 66%
Medical treatment of advanced non-small cell lung cancer in elderly patients: A review of the role of chemotherapy and targeted agents 2013 13 34 59%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PULM DIS 1 8 62% 0.3% 8
2 DIS MANAGEMENT TEAM LUNG CANC 5 63% 0.2% 5
3 PULM DIS 8 5 63% 0.2% 5
4 PULM DIS 2 3 50% 0.2% 5
5 CHEST DIS 1 3 100% 0.1% 3
6 CHEST DIS 2 3 100% 0.1% 3
7 CHEST DIS 7 3 100% 0.1% 3
8 MULTIDISCIPLINARY THORAC ONCOL PROGRAM 3 17% 0.7% 17
9 CLIN 7 3 60% 0.1% 3
10 LUNG THORAC CANC PROGRAM 3 60% 0.1% 3

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000235424 PEMETREXED//MULTITARGETED ANTIFOLATE//NONSQUAMOUS
2 0.0000174786 STAGE III//LOCALLY ADVANCED NON SMALL CELL LUNG CANCER//ACUTE ESOPHAGITIS
3 0.0000100427 N2 DISEASE//PLEURAL INVASION//STAGE IIIA
4 0.0000095613 GEMCITABINE//TROXACITABINE//DEOXYCYTIDINE KINASE
5 0.0000095175 VINFLUNINE//VINCA ALKALOIDS//ONCOL PHARMACOKINET
6 0.0000084718 METASTATIC BREAST CANCER//VINORELBINE//DOCETAXEL
7 0.0000075701 SMALL CELL LUNG CANCER//AMRUBICIN//PROPHYLACTIC CRANIAL IRRADIATION
8 0.0000062729 NAB PACLITAXEL//CREMOPHOR EL//NEW MAT BIOL
9 0.0000061729 CALVERT FORMULA//CHATELUT FORMULA//SKI 2053R
10 0.0000061484 LIPOSOMAL CISPLATIN//LIPOPLATIN//SPI 077